nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—breast cancer	0.174	1	CbGaD
Trametinib—CYP2C8—Lapatinib—breast cancer	0.0408	0.11	CbGbCtD
Trametinib—CYP3A4—Exemestane—breast cancer	0.0327	0.0886	CbGbCtD
Trametinib—CYP2C8—Raloxifene—breast cancer	0.0309	0.0837	CbGbCtD
Trametinib—CYP3A4—Letrozole—breast cancer	0.0278	0.0753	CbGbCtD
Trametinib—CYP3A4—Anastrozole—breast cancer	0.0248	0.0671	CbGbCtD
Trametinib—CYP3A4—Toremifene—breast cancer	0.0227	0.0614	CbGbCtD
Trametinib—CYP3A4—Fulvestrant—breast cancer	0.0211	0.0571	CbGbCtD
Trametinib—CYP2C8—Tamoxifen—breast cancer	0.0204	0.0553	CbGbCtD
Trametinib—CYP3A4—Thiotepa—breast cancer	0.0188	0.0509	CbGbCtD
Trametinib—CYP3A4—Ixabepilone—breast cancer	0.0172	0.0465	CbGbCtD
Trametinib—CYP3A4—Lapatinib—breast cancer	0.0165	0.0448	CbGbCtD
Trametinib—CYP2C8—Paclitaxel—breast cancer	0.0159	0.043	CbGbCtD
Trametinib—CYP2C8—Fluorouracil—breast cancer	0.015	0.0408	CbGbCtD
Trametinib—CYP3A4—Raloxifene—breast cancer	0.0125	0.0339	CbGbCtD
Trametinib—CYP3A4—Vinorelbine—breast cancer	0.00917	0.0248	CbGbCtD
Trametinib—CYP3A4—Tamoxifen—breast cancer	0.00828	0.0224	CbGbCtD
Trametinib—CYP3A4—Mitoxantrone—breast cancer	0.00808	0.0219	CbGbCtD
Trametinib—CYP3A4—Paclitaxel—breast cancer	0.00644	0.0175	CbGbCtD
Trametinib—CYP3A4—Irinotecan—breast cancer	0.00636	0.0172	CbGbCtD
Trametinib—CYP3A4—Vinblastine—breast cancer	0.00565	0.0153	CbGbCtD
Trametinib—CYP3A4—Docetaxel—breast cancer	0.00466	0.0126	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—breast cancer	0.00347	0.00941	CbGbCtD
Trametinib—MAP2K2—nipple—breast cancer	0.00309	0.0719	CbGeAlD
Trametinib—MAP2K1—embryo—breast cancer	0.0029	0.0674	CbGeAlD
Trametinib—MAP2K1—epithelium—breast cancer	0.00236	0.055	CbGeAlD
Trametinib—MAP2K1—skin of body—breast cancer	0.00225	0.0523	CbGeAlD
Trametinib—MAP2K2—skin of body—breast cancer	0.00198	0.046	CbGeAlD
Trametinib—MAP2K1—adipose tissue—breast cancer	0.00191	0.0444	CbGeAlD
Trametinib—MAP2K2—endometrium—breast cancer	0.00187	0.0434	CbGeAlD
Trametinib—MAP2K1—female reproductive system—breast cancer	0.00176	0.0408	CbGeAlD
Trametinib—MAP2K2—uterus—breast cancer	0.00172	0.04	CbGeAlD
Trametinib—MAP2K1—adrenal gland—breast cancer	0.00171	0.0399	CbGeAlD
Trametinib—MAP2K2—pituitary gland—breast cancer	0.00169	0.0393	CbGeAlD
Trametinib—MAP2K2—adipose tissue—breast cancer	0.00168	0.0391	CbGeAlD
Trametinib—MAP2K1—bone marrow—breast cancer	0.00166	0.0386	CbGeAlD
Trametinib—MAP2K1—female gonad—breast cancer	0.0016	0.0372	CbGeAlD
Trametinib—MAP2K2—female reproductive system—breast cancer	0.00155	0.036	CbGeAlD
Trametinib—MAP2K2—adrenal gland—breast cancer	0.00151	0.0351	CbGeAlD
Trametinib—MAP2K1—endocrine gland—breast cancer	0.00149	0.0346	CbGeAlD
Trametinib—MAP2K2—bone marrow—breast cancer	0.00146	0.0339	CbGeAlD
Trametinib—MAP2K2—female gonad—breast cancer	0.00141	0.0327	CbGeAlD
Trametinib—MAP2K2—endocrine gland—breast cancer	0.00131	0.0304	CbGeAlD
Trametinib—CYP2C8—mammary gland—breast cancer	0.00129	0.0301	CbGeAlD
Trametinib—MAP2K1—lymph node—breast cancer	0.00103	0.0239	CbGeAlD
Trametinib—MAP2K2—lymph node—breast cancer	0.000905	0.021	CbGeAlD
Trametinib—CYP2C8—endometrium—breast cancer	0.000646	0.015	CbGeAlD
Trametinib—CYP2C8—pituitary gland—breast cancer	0.000585	0.0136	CbGeAlD
Trametinib—CYP2C8—female reproductive system—breast cancer	0.000536	0.0125	CbGeAlD
Trametinib—CYP2C8—endocrine gland—breast cancer	0.000453	0.0105	CbGeAlD
Trametinib—CYP3A4—female reproductive system—breast cancer	0.000363	0.00843	CbGeAlD
Trametinib—CYP3A4—endocrine gland—breast cancer	0.000307	0.00714	CbGeAlD
Trametinib—Haemorrhage—Methotrexate—breast cancer	4.22e-05	0.000195	CcSEcCtD
Trametinib—Asthenia—Gemcitabine—breast cancer	4.21e-05	0.000194	CcSEcCtD
Trametinib—Myalgia—Capecitabine—breast cancer	4.2e-05	0.000194	CcSEcCtD
Trametinib—Arthralgia—Capecitabine—breast cancer	4.2e-05	0.000194	CcSEcCtD
Trametinib—Constipation—Paclitaxel—breast cancer	4.2e-05	0.000194	CcSEcCtD
Trametinib—Haematuria—Epirubicin—breast cancer	4.19e-05	0.000194	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	4.17e-05	0.000193	CcSEcCtD
Trametinib—Urinary tract disorder—Methotrexate—breast cancer	4.17e-05	0.000193	CcSEcCtD
Trametinib—Oedema—Docetaxel—breast cancer	4.16e-05	0.000192	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—breast cancer	4.15e-05	0.000192	CcSEcCtD
Trametinib—Pruritus—Gemcitabine—breast cancer	4.15e-05	0.000192	CcSEcCtD
Trametinib—Nausea—Thiotepa—breast cancer	4.14e-05	0.000191	CcSEcCtD
Trametinib—Urethral disorder—Methotrexate—breast cancer	4.14e-05	0.000191	CcSEcCtD
Trametinib—Infection—Docetaxel—breast cancer	4.13e-05	0.000191	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—breast cancer	4.12e-05	0.00019	CcSEcCtD
Trametinib—Diarrhoea—Mitoxantrone—breast cancer	4.12e-05	0.00019	CcSEcCtD
Trametinib—Diarrhoea—Irinotecan—breast cancer	4.12e-05	0.00019	CcSEcCtD
Trametinib—Dry mouth—Capecitabine—breast cancer	4.11e-05	0.00019	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—breast cancer	4.08e-05	0.000188	CcSEcCtD
Trametinib—Pruritus—Fluorouracil—breast cancer	4.08e-05	0.000188	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—breast cancer	4.07e-05	0.000188	CcSEcCtD
Trametinib—Infestation—Doxorubicin—breast cancer	4.07e-05	0.000188	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—breast cancer	4.07e-05	0.000188	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—breast cancer	4.04e-05	0.000187	CcSEcCtD
Trametinib—Oedema—Capecitabine—breast cancer	4.03e-05	0.000186	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—breast cancer	4.02e-05	0.000186	CcSEcCtD
Trametinib—Gastrointestinal pain—Paclitaxel—breast cancer	4.01e-05	0.000185	CcSEcCtD
Trametinib—Diarrhoea—Gemcitabine—breast cancer	4.01e-05	0.000185	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—breast cancer	4e-05	0.000185	CcSEcCtD
Trametinib—Infection—Capecitabine—breast cancer	4e-05	0.000185	CcSEcCtD
Trametinib—Dizziness—Irinotecan—breast cancer	3.98e-05	0.000184	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—breast cancer	3.97e-05	0.000183	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—breast cancer	3.97e-05	0.000183	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—breast cancer	3.96e-05	0.000183	CcSEcCtD
Trametinib—Nervous system disorder—Capecitabine—breast cancer	3.95e-05	0.000182	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—breast cancer	3.95e-05	0.000182	CcSEcCtD
Trametinib—Eye disorder—Methotrexate—breast cancer	3.94e-05	0.000182	CcSEcCtD
Trametinib—Diarrhoea—Fluorouracil—breast cancer	3.94e-05	0.000182	CcSEcCtD
Trametinib—Thrombocytopenia—Capecitabine—breast cancer	3.94e-05	0.000182	CcSEcCtD
Trametinib—Cardiac disorder—Methotrexate—breast cancer	3.92e-05	0.000181	CcSEcCtD
Trametinib—Skin disorder—Capecitabine—breast cancer	3.91e-05	0.000181	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—breast cancer	3.9e-05	0.00018	CcSEcCtD
Trametinib—Hyperhidrosis—Capecitabine—breast cancer	3.89e-05	0.00018	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—breast cancer	3.89e-05	0.00018	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—breast cancer	3.88e-05	0.000179	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—breast cancer	3.88e-05	0.000179	CcSEcCtD
Trametinib—Body temperature increased—Paclitaxel—breast cancer	3.88e-05	0.000179	CcSEcCtD
Trametinib—Abdominal pain—Paclitaxel—breast cancer	3.88e-05	0.000179	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—breast cancer	3.87e-05	0.000179	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—breast cancer	3.84e-05	0.000177	CcSEcCtD
Trametinib—Angiopathy—Methotrexate—breast cancer	3.83e-05	0.000177	CcSEcCtD
Trametinib—Vomiting—Mitoxantrone—breast cancer	3.83e-05	0.000177	CcSEcCtD
Trametinib—Vomiting—Irinotecan—breast cancer	3.83e-05	0.000177	CcSEcCtD
Trametinib—Dizziness—Fluorouracil—breast cancer	3.81e-05	0.000176	CcSEcCtD
Trametinib—Mediastinal disorder—Methotrexate—breast cancer	3.8e-05	0.000176	CcSEcCtD
Trametinib—Rash—Mitoxantrone—breast cancer	3.79e-05	0.000175	CcSEcCtD
Trametinib—Rash—Irinotecan—breast cancer	3.79e-05	0.000175	CcSEcCtD
Trametinib—Dermatitis—Mitoxantrone—breast cancer	3.79e-05	0.000175	CcSEcCtD
Trametinib—Dermatitis—Irinotecan—breast cancer	3.79e-05	0.000175	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—breast cancer	3.79e-05	0.000175	CcSEcCtD
Trametinib—Chills—Methotrexate—breast cancer	3.79e-05	0.000175	CcSEcCtD
Trametinib—Headache—Mitoxantrone—breast cancer	3.77e-05	0.000174	CcSEcCtD
Trametinib—Headache—Irinotecan—breast cancer	3.77e-05	0.000174	CcSEcCtD
Trametinib—Insomnia—Docetaxel—breast cancer	3.76e-05	0.000174	CcSEcCtD
Trametinib—Vomiting—Gemcitabine—breast cancer	3.73e-05	0.000172	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—breast cancer	3.72e-05	0.000172	CcSEcCtD
Trametinib—Mental disorder—Methotrexate—breast cancer	3.7e-05	0.000171	CcSEcCtD
Trametinib—Rash—Gemcitabine—breast cancer	3.7e-05	0.000171	CcSEcCtD
Trametinib—Dermatitis—Gemcitabine—breast cancer	3.69e-05	0.000171	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—breast cancer	3.69e-05	0.00017	CcSEcCtD
Trametinib—Erythema—Methotrexate—breast cancer	3.67e-05	0.00017	CcSEcCtD
Trametinib—Malnutrition—Methotrexate—breast cancer	3.67e-05	0.00017	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—breast cancer	3.67e-05	0.00017	CcSEcCtD
Trametinib—Headache—Gemcitabine—breast cancer	3.67e-05	0.00017	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Capecitabine—breast cancer	3.67e-05	0.00017	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—breast cancer	3.67e-05	0.000169	CcSEcCtD
Trametinib—Vomiting—Fluorouracil—breast cancer	3.66e-05	0.000169	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—breast cancer	3.65e-05	0.000169	CcSEcCtD
Trametinib—Insomnia—Capecitabine—breast cancer	3.64e-05	0.000168	CcSEcCtD
Trametinib—Rash—Fluorouracil—breast cancer	3.63e-05	0.000168	CcSEcCtD
Trametinib—Dermatitis—Fluorouracil—breast cancer	3.63e-05	0.000168	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—breast cancer	3.62e-05	0.000167	CcSEcCtD
Trametinib—Headache—Fluorouracil—breast cancer	3.61e-05	0.000167	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—breast cancer	3.61e-05	0.000167	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—breast cancer	3.6e-05	0.000166	CcSEcCtD
Trametinib—Dysgeusia—Methotrexate—breast cancer	3.6e-05	0.000166	CcSEcCtD
Trametinib—Gastrointestinal disorder—Docetaxel—breast cancer	3.59e-05	0.000166	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—breast cancer	3.59e-05	0.000166	CcSEcCtD
Trametinib—Fatigue—Docetaxel—breast cancer	3.59e-05	0.000166	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—breast cancer	3.58e-05	0.000166	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—breast cancer	3.58e-05	0.000165	CcSEcCtD
Trametinib—Nausea—Irinotecan—breast cancer	3.57e-05	0.000165	CcSEcCtD
Trametinib—Nausea—Mitoxantrone—breast cancer	3.57e-05	0.000165	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—breast cancer	3.56e-05	0.000164	CcSEcCtD
Trametinib—Constipation—Docetaxel—breast cancer	3.56e-05	0.000164	CcSEcCtD
Trametinib—Back pain—Methotrexate—breast cancer	3.55e-05	0.000164	CcSEcCtD
Trametinib—Chills—Epirubicin—breast cancer	3.54e-05	0.000164	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—breast cancer	3.53e-05	0.000163	CcSEcCtD
Trametinib—Asthenia—Paclitaxel—breast cancer	3.52e-05	0.000163	CcSEcCtD
Trametinib—Decreased appetite—Capecitabine—breast cancer	3.5e-05	0.000162	CcSEcCtD
Trametinib—Nausea—Gemcitabine—breast cancer	3.48e-05	0.000161	CcSEcCtD
Trametinib—Gastrointestinal disorder—Capecitabine—breast cancer	3.48e-05	0.000161	CcSEcCtD
Trametinib—Fatigue—Capecitabine—breast cancer	3.47e-05	0.00016	CcSEcCtD
Trametinib—Pruritus—Paclitaxel—breast cancer	3.47e-05	0.00016	CcSEcCtD
Trametinib—Vision blurred—Methotrexate—breast cancer	3.46e-05	0.00016	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—breast cancer	3.46e-05	0.00016	CcSEcCtD
Trametinib—Constipation—Capecitabine—breast cancer	3.44e-05	0.000159	CcSEcCtD
Trametinib—Erythema—Epirubicin—breast cancer	3.44e-05	0.000159	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—breast cancer	3.44e-05	0.000159	CcSEcCtD
Trametinib—Nausea—Fluorouracil—breast cancer	3.42e-05	0.000158	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—breast cancer	3.41e-05	0.000158	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—breast cancer	3.4e-05	0.000157	CcSEcCtD
Trametinib—Anaemia—Methotrexate—breast cancer	3.4e-05	0.000157	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—breast cancer	3.39e-05	0.000157	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—breast cancer	3.37e-05	0.000156	CcSEcCtD
Trametinib—Diarrhoea—Paclitaxel—breast cancer	3.36e-05	0.000155	CcSEcCtD
Trametinib—Back pain—Epirubicin—breast cancer	3.33e-05	0.000154	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—breast cancer	3.32e-05	0.000153	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—breast cancer	3.31e-05	0.000153	CcSEcCtD
Trametinib—Gastrointestinal pain—Capecitabine—breast cancer	3.29e-05	0.000152	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—breast cancer	3.29e-05	0.000152	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—breast cancer	3.29e-05	0.000152	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—breast cancer	3.29e-05	0.000152	CcSEcCtD
Trametinib—Leukopenia—Methotrexate—breast cancer	3.29e-05	0.000152	CcSEcCtD
Trametinib—Chills—Doxorubicin—breast cancer	3.28e-05	0.000151	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—breast cancer	3.26e-05	0.000151	CcSEcCtD
Trametinib—Dizziness—Paclitaxel—breast cancer	3.25e-05	0.00015	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—breast cancer	3.24e-05	0.00015	CcSEcCtD
Trametinib—Cough—Methotrexate—breast cancer	3.21e-05	0.000148	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—breast cancer	3.2e-05	0.000148	CcSEcCtD
Trametinib—Body temperature increased—Capecitabine—breast cancer	3.18e-05	0.000147	CcSEcCtD
Trametinib—Abdominal pain—Capecitabine—breast cancer	3.18e-05	0.000147	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—breast cancer	3.18e-05	0.000147	CcSEcCtD
Trametinib—Erythema—Doxorubicin—breast cancer	3.18e-05	0.000147	CcSEcCtD
Trametinib—Anaemia—Epirubicin—breast cancer	3.18e-05	0.000147	CcSEcCtD
Trametinib—Arthralgia—Methotrexate—breast cancer	3.13e-05	0.000144	CcSEcCtD
Trametinib—Myalgia—Methotrexate—breast cancer	3.13e-05	0.000144	CcSEcCtD
Trametinib—Vomiting—Paclitaxel—breast cancer	3.12e-05	0.000144	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—breast cancer	3.11e-05	0.000144	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	3.11e-05	0.000143	CcSEcCtD
Trametinib—Rash—Paclitaxel—breast cancer	3.09e-05	0.000143	CcSEcCtD
Trametinib—Dermatitis—Paclitaxel—breast cancer	3.09e-05	0.000143	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—breast cancer	3.08e-05	0.000142	CcSEcCtD
Trametinib—Back pain—Doxorubicin—breast cancer	3.08e-05	0.000142	CcSEcCtD
Trametinib—Headache—Paclitaxel—breast cancer	3.07e-05	0.000142	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—breast cancer	3.06e-05	0.000141	CcSEcCtD
Trametinib—Cough—Epirubicin—breast cancer	3e-05	0.000139	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—breast cancer	3e-05	0.000138	CcSEcCtD
Trametinib—Asthenia—Docetaxel—breast cancer	2.98e-05	0.000138	CcSEcCtD
Trametinib—Infection—Methotrexate—breast cancer	2.98e-05	0.000138	CcSEcCtD
Trametinib—Hypertension—Epirubicin—breast cancer	2.97e-05	0.000137	CcSEcCtD
Trametinib—Pruritus—Docetaxel—breast cancer	2.94e-05	0.000136	CcSEcCtD
Trametinib—Nervous system disorder—Methotrexate—breast cancer	2.94e-05	0.000136	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—breast cancer	2.94e-05	0.000136	CcSEcCtD
Trametinib—Thrombocytopenia—Methotrexate—breast cancer	2.94e-05	0.000136	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—breast cancer	2.93e-05	0.000135	CcSEcCtD
Trametinib—Myalgia—Epirubicin—breast cancer	2.93e-05	0.000135	CcSEcCtD
Trametinib—Nausea—Paclitaxel—breast cancer	2.91e-05	0.000135	CcSEcCtD
Trametinib—Skin disorder—Methotrexate—breast cancer	2.91e-05	0.000135	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	2.91e-05	0.000134	CcSEcCtD
Trametinib—Hyperhidrosis—Methotrexate—breast cancer	2.9e-05	0.000134	CcSEcCtD
Trametinib—Asthenia—Capecitabine—breast cancer	2.89e-05	0.000133	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—breast cancer	2.86e-05	0.000132	CcSEcCtD
Trametinib—Pruritus—Capecitabine—breast cancer	2.85e-05	0.000132	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—breast cancer	2.85e-05	0.000132	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—breast cancer	2.85e-05	0.000131	CcSEcCtD
Trametinib—Oedema—Epirubicin—breast cancer	2.81e-05	0.00013	CcSEcCtD
Trametinib—Infection—Epirubicin—breast cancer	2.79e-05	0.000129	CcSEcCtD
Trametinib—Cough—Doxorubicin—breast cancer	2.78e-05	0.000128	CcSEcCtD
Trametinib—Diarrhoea—Capecitabine—breast cancer	2.76e-05	0.000127	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—breast cancer	2.75e-05	0.000127	CcSEcCtD
Trametinib—Dizziness—Docetaxel—breast cancer	2.75e-05	0.000127	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—breast cancer	2.75e-05	0.000127	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—breast cancer	2.75e-05	0.000127	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Methotrexate—breast cancer	2.73e-05	0.000126	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—breast cancer	2.73e-05	0.000126	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—breast cancer	2.71e-05	0.000125	CcSEcCtD
Trametinib—Insomnia—Methotrexate—breast cancer	2.71e-05	0.000125	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—breast cancer	2.71e-05	0.000125	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—breast cancer	2.71e-05	0.000125	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	2.69e-05	0.000124	CcSEcCtD
Trametinib—Dizziness—Capecitabine—breast cancer	2.66e-05	0.000123	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—breast cancer	2.65e-05	0.000122	CcSEcCtD
Trametinib—Vomiting—Docetaxel—breast cancer	2.64e-05	0.000122	CcSEcCtD
Trametinib—Rash—Docetaxel—breast cancer	2.62e-05	0.000121	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—breast cancer	2.62e-05	0.000121	CcSEcCtD
Trametinib—Decreased appetite—Methotrexate—breast cancer	2.61e-05	0.00012	CcSEcCtD
Trametinib—Headache—Docetaxel—breast cancer	2.61e-05	0.00012	CcSEcCtD
Trametinib—Oedema—Doxorubicin—breast cancer	2.6e-05	0.00012	CcSEcCtD
Trametinib—Gastrointestinal disorder—Methotrexate—breast cancer	2.59e-05	0.00012	CcSEcCtD
Trametinib—Fatigue—Methotrexate—breast cancer	2.58e-05	0.000119	CcSEcCtD
Trametinib—Infection—Doxorubicin—breast cancer	2.58e-05	0.000119	CcSEcCtD
Trametinib—Vomiting—Capecitabine—breast cancer	2.56e-05	0.000118	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—breast cancer	2.56e-05	0.000118	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—breast cancer	2.55e-05	0.000118	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—breast cancer	2.54e-05	0.000117	CcSEcCtD
Trametinib—Rash—Capecitabine—breast cancer	2.54e-05	0.000117	CcSEcCtD
Trametinib—Insomnia—Epirubicin—breast cancer	2.54e-05	0.000117	CcSEcCtD
Trametinib—Dermatitis—Capecitabine—breast cancer	2.54e-05	0.000117	CcSEcCtD
Trametinib—Headache—Capecitabine—breast cancer	2.52e-05	0.000117	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—breast cancer	2.52e-05	0.000116	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—breast cancer	2.51e-05	0.000116	CcSEcCtD
Trametinib—Nausea—Docetaxel—breast cancer	2.47e-05	0.000114	CcSEcCtD
Trametinib—Gastrointestinal pain—Methotrexate—breast cancer	2.45e-05	0.000113	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—breast cancer	2.44e-05	0.000113	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—breast cancer	2.42e-05	0.000112	CcSEcCtD
Trametinib—Fatigue—Epirubicin—breast cancer	2.42e-05	0.000112	CcSEcCtD
Trametinib—Constipation—Epirubicin—breast cancer	2.4e-05	0.000111	CcSEcCtD
Trametinib—Nausea—Capecitabine—breast cancer	2.39e-05	0.000111	CcSEcCtD
Trametinib—Abdominal pain—Methotrexate—breast cancer	2.37e-05	0.000109	CcSEcCtD
Trametinib—Body temperature increased—Methotrexate—breast cancer	2.37e-05	0.000109	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.37e-05	0.000109	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—breast cancer	2.35e-05	0.000108	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—breast cancer	2.29e-05	0.000106	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—breast cancer	2.26e-05	0.000104	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—breast cancer	2.24e-05	0.000104	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—breast cancer	2.24e-05	0.000103	CcSEcCtD
Trametinib—Constipation—Doxorubicin—breast cancer	2.22e-05	0.000103	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—breast cancer	2.22e-05	0.000102	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—breast cancer	2.22e-05	0.000102	CcSEcCtD
Trametinib—Asthenia—Methotrexate—breast cancer	2.15e-05	9.94e-05	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—breast cancer	2.12e-05	9.81e-05	CcSEcCtD
Trametinib—Pruritus—Methotrexate—breast cancer	2.12e-05	9.8e-05	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—breast cancer	2.05e-05	9.48e-05	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—breast cancer	2.05e-05	9.48e-05	CcSEcCtD
Trametinib—Diarrhoea—Methotrexate—breast cancer	2.05e-05	9.48e-05	CcSEcCtD
Trametinib—Asthenia—Epirubicin—breast cancer	2.01e-05	9.3e-05	CcSEcCtD
Trametinib—Pruritus—Epirubicin—breast cancer	1.98e-05	9.17e-05	CcSEcCtD
Trametinib—Dizziness—Methotrexate—breast cancer	1.98e-05	9.16e-05	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—breast cancer	1.92e-05	8.87e-05	CcSEcCtD
Trametinib—Vomiting—Methotrexate—breast cancer	1.91e-05	8.81e-05	CcSEcCtD
Trametinib—Rash—Methotrexate—breast cancer	1.89e-05	8.73e-05	CcSEcCtD
Trametinib—Dermatitis—Methotrexate—breast cancer	1.89e-05	8.72e-05	CcSEcCtD
Trametinib—Headache—Methotrexate—breast cancer	1.88e-05	8.68e-05	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—breast cancer	1.86e-05	8.6e-05	CcSEcCtD
Trametinib—Dizziness—Epirubicin—breast cancer	1.86e-05	8.57e-05	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—breast cancer	1.84e-05	8.48e-05	CcSEcCtD
Trametinib—Vomiting—Epirubicin—breast cancer	1.78e-05	8.24e-05	CcSEcCtD
Trametinib—Nausea—Methotrexate—breast cancer	1.78e-05	8.23e-05	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—breast cancer	1.78e-05	8.21e-05	CcSEcCtD
Trametinib—Rash—Epirubicin—breast cancer	1.77e-05	8.17e-05	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—breast cancer	1.77e-05	8.16e-05	CcSEcCtD
Trametinib—Headache—Epirubicin—breast cancer	1.76e-05	8.12e-05	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—breast cancer	1.72e-05	7.93e-05	CcSEcCtD
Trametinib—Nausea—Epirubicin—breast cancer	1.67e-05	7.7e-05	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—breast cancer	1.65e-05	7.63e-05	CcSEcCtD
Trametinib—Rash—Doxorubicin—breast cancer	1.64e-05	7.56e-05	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—breast cancer	1.64e-05	7.55e-05	CcSEcCtD
Trametinib—Headache—Doxorubicin—breast cancer	1.63e-05	7.51e-05	CcSEcCtD
Trametinib—Nausea—Doxorubicin—breast cancer	1.54e-05	7.12e-05	CcSEcCtD
Trametinib—MAP2K2—Immune System—MAPK8—breast cancer	3.24e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KIT—breast cancer	3.23e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—breast cancer	3.23e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—breast cancer	3.23e-06	1.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—JUN—breast cancer	3.2e-06	1.63e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ESR1—breast cancer	3.2e-06	1.62e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC2A1—breast cancer	3.2e-06	1.62e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NQO1—breast cancer	3.2e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGF—breast cancer	3.2e-06	1.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—breast cancer	3.18e-06	1.61e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FN1—breast cancer	3.16e-06	1.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—breast cancer	3.14e-06	1.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMMR—breast cancer	3.13e-06	1.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA3—breast cancer	3.13e-06	1.59e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCC1—breast cancer	3.13e-06	1.59e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	3.13e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKBIA—breast cancer	3.12e-06	1.58e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP3A4—breast cancer	3.12e-06	1.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1B—breast cancer	3.11e-06	1.58e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDKN1A—breast cancer	3.1e-06	1.58e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	3.1e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—breast cancer	3.1e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—MAPK3—breast cancer	3.1e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—breast cancer	3.09e-06	1.57e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—breast cancer	3.07e-06	1.56e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1B1—breast cancer	3.07e-06	1.56e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—breast cancer	3.07e-06	1.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CDKN1A—breast cancer	3.06e-06	1.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—breast cancer	3.06e-06	1.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—breast cancer	3.04e-06	1.54e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARGC1B—breast cancer	3.03e-06	1.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK8—breast cancer	3.03e-06	1.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—breast cancer	3.02e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—breast cancer	3.02e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KIT—breast cancer	3.02e-06	1.53e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HSP90AA1—breast cancer	3.01e-06	1.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGF—breast cancer	2.99e-06	1.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—breast cancer	2.96e-06	1.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IGF1—breast cancer	2.96e-06	1.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT2—breast cancer	2.96e-06	1.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—breast cancer	2.95e-06	1.49e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—breast cancer	2.93e-06	1.49e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NCOA1—breast cancer	2.93e-06	1.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—MAPK3—breast cancer	2.9e-06	1.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP19A1—breast cancer	2.88e-06	1.46e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STK11—breast cancer	2.88e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—breast cancer	2.87e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CDKN1A—breast cancer	2.87e-06	1.45e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA4—breast cancer	2.87e-06	1.45e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CA9—breast cancer	2.87e-06	1.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—breast cancer	2.86e-06	1.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—breast cancer	2.84e-06	1.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—breast cancer	2.84e-06	1.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—breast cancer	2.83e-06	1.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MAPK3—breast cancer	2.83e-06	1.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SERPINE1—breast cancer	2.81e-06	1.43e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA2—breast cancer	2.79e-06	1.42e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPX2—breast cancer	2.79e-06	1.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—breast cancer	2.78e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—breast cancer	2.77e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IGF1—breast cancer	2.77e-06	1.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT2—breast cancer	2.77e-06	1.4e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SULT1A1—breast cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPX4—breast cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—breast cancer	2.76e-06	1.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—breast cancer	2.73e-06	1.39e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.71e-06	1.37e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH1—breast cancer	2.69e-06	1.37e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTA1—breast cancer	2.69e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—breast cancer	2.69e-06	1.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOS3—breast cancer	2.68e-06	1.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—COMT—breast cancer	2.68e-06	1.36e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—breast cancer	2.67e-06	1.35e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NAT2—breast cancer	2.66e-06	1.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—breast cancer	2.66e-06	1.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—breast cancer	2.65e-06	1.35e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MAPK3—breast cancer	2.65e-06	1.34e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—HMOX1—breast cancer	2.63e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SERPINE1—breast cancer	2.63e-06	1.33e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ITPR1—breast cancer	2.63e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MAPK3—breast cancer	2.61e-06	1.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—breast cancer	2.6e-06	1.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—breast cancer	2.56e-06	1.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—breast cancer	2.56e-06	1.3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—breast cancer	2.55e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—breast cancer	2.54e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—breast cancer	2.54e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAF1—breast cancer	2.54e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—breast cancer	2.53e-06	1.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RELA—breast cancer	2.53e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ABCB1—breast cancer	2.53e-06	1.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—breast cancer	2.52e-06	1.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOS3—breast cancer	2.51e-06	1.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—breast cancer	2.51e-06	1.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—breast cancer	2.48e-06	1.26e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—breast cancer	2.48e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—breast cancer	2.48e-06	1.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MTOR—breast cancer	2.48e-06	1.26e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NCOR1—breast cancer	2.45e-06	1.24e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PLA2G4A—breast cancer	2.45e-06	1.24e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTM1—breast cancer	2.45e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MAPK3—breast cancer	2.44e-06	1.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—breast cancer	2.39e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—breast cancer	2.38e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—breast cancer	2.38e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—breast cancer	2.38e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—breast cancer	2.38e-06	1.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAF1—breast cancer	2.37e-06	1.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—breast cancer	2.37e-06	1.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—breast cancer	2.37e-06	1.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RELA—breast cancer	2.36e-06	1.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—breast cancer	2.35e-06	1.19e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GPX1—breast cancer	2.35e-06	1.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—breast cancer	2.35e-06	1.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MED12—breast cancer	2.34e-06	1.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DPYD—breast cancer	2.34e-06	1.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—breast cancer	2.34e-06	1.19e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1B—breast cancer	2.32e-06	1.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—breast cancer	2.32e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP1A1—breast cancer	2.32e-06	1.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MTOR—breast cancer	2.32e-06	1.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—breast cancer	2.32e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ERCC2—breast cancer	2.3e-06	1.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALDOA—breast cancer	2.3e-06	1.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—breast cancer	2.28e-06	1.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—breast cancer	2.28e-06	1.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL6—breast cancer	2.26e-06	1.15e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA3—breast cancer	2.23e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—breast cancer	2.23e-06	1.13e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—breast cancer	2.22e-06	1.13e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A2—breast cancer	2.22e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—JUN—breast cancer	2.21e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—breast cancer	2.21e-06	1.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—breast cancer	2.2e-06	1.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—breast cancer	2.2e-06	1.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—breast cancer	2.19e-06	1.11e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1B—breast cancer	2.18e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CPT1A—breast cancer	2.17e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTR—breast cancer	2.17e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCG2—breast cancer	2.17e-06	1.1e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—MTHFR—breast cancer	2.17e-06	1.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—breast cancer	2.16e-06	1.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—breast cancer	2.16e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—breast cancer	2.15e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN1A—breast cancer	2.15e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—breast cancer	2.14e-06	1.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—breast cancer	2.13e-06	1.08e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HPGDS—breast cancer	2.13e-06	1.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—breast cancer	2.13e-06	1.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL6—breast cancer	2.12e-06	1.07e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HBA1—breast cancer	2.12e-06	1.07e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK8—breast cancer	2.09e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—breast cancer	2.09e-06	1.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—breast cancer	2.07e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JUN—breast cancer	2.07e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL6—breast cancer	2.07e-06	1.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—breast cancer	2.07e-06	1.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ACHE—breast cancer	2.07e-06	1.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—breast cancer	2.05e-06	1.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—breast cancer	2.02e-06	1.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—breast cancer	2.02e-06	1.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—breast cancer	2.01e-06	1.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN1A—breast cancer	2.01e-06	1.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—breast cancer	2e-06	1.02e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAV1—breast cancer	2e-06	1.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—breast cancer	2e-06	1.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—breast cancer	1.99e-06	1.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK8—breast cancer	1.96e-06	9.94e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP17A1—breast cancer	1.96e-06	9.92e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—breast cancer	1.95e-06	9.91e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ENO1—breast cancer	1.94e-06	9.82e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS1—breast cancer	1.94e-06	9.82e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL6—breast cancer	1.94e-06	9.82e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—breast cancer	1.93e-06	9.81e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—breast cancer	1.91e-06	9.71e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—IL6—breast cancer	1.91e-06	9.69e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.91e-06	9.69e-06	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—breast cancer	1.91e-06	9.68e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2D6—breast cancer	1.9e-06	9.63e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—breast cancer	1.87e-06	9.47e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA2—breast cancer	1.86e-06	9.46e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—breast cancer	1.86e-06	9.42e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MAPK3—breast cancer	1.83e-06	9.28e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—breast cancer	1.82e-06	9.24e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—breast cancer	1.81e-06	9.18e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—FASN—breast cancer	1.81e-06	9.17e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BCHE—breast cancer	1.8e-06	9.13e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—breast cancer	1.79e-06	9.09e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—IL6—breast cancer	1.79e-06	9.07e-06	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—breast cancer	1.79e-06	9.06e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—breast cancer	1.78e-06	9.03e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—breast cancer	1.78e-06	9.02e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—breast cancer	1.77e-06	9e-06	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—breast cancer	1.76e-06	8.94e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—breast cancer	1.74e-06	8.83e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A1—breast cancer	1.72e-06	8.71e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NQO1—breast cancer	1.72e-06	8.71e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MAPK3—breast cancer	1.71e-06	8.68e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—breast cancer	1.66e-06	8.45e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—breast cancer	1.66e-06	8.42e-06	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—breast cancer	1.65e-06	8.36e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1B1—breast cancer	1.65e-06	8.35e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—breast cancer	1.64e-06	8.34e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—breast cancer	1.63e-06	8.26e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HSP90AA1—breast cancer	1.61e-06	8.19e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—breast cancer	1.6e-06	8.12e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—ALB—breast cancer	1.58e-06	8.02e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOA1—breast cancer	1.57e-06	7.97e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STK11—breast cancer	1.55e-06	7.85e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP19A1—breast cancer	1.55e-06	7.85e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—breast cancer	1.54e-06	7.8e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NOS3—breast cancer	1.51e-06	7.67e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—breast cancer	1.51e-06	7.66e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—breast cancer	1.46e-06	7.41e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—COMT—breast cancer	1.44e-06	7.3e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—breast cancer	1.43e-06	7.27e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—breast cancer	1.41e-06	7.17e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—HMOX1—breast cancer	1.41e-06	7.17e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ITPR1—breast cancer	1.41e-06	7.15e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—breast cancer	1.4e-06	7.09e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—breast cancer	1.39e-06	7.08e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—breast cancer	1.38e-06	7.01e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—breast cancer	1.37e-06	6.94e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ABCB1—breast cancer	1.36e-06	6.88e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL6—breast cancer	1.34e-06	6.79e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—breast cancer	1.33e-06	6.75e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.32e-06	6.68e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTM1—breast cancer	1.32e-06	6.68e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOR1—breast cancer	1.32e-06	6.68e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—breast cancer	1.31e-06	6.63e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GPX1—breast cancer	1.26e-06	6.39e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL6—breast cancer	1.25e-06	6.35e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP1A1—breast cancer	1.25e-06	6.33e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ERCC2—breast cancer	1.24e-06	6.28e-06	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—breast cancer	1.23e-06	6.26e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—breast cancer	1.21e-06	6.12e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—MTHFR—breast cancer	1.16e-06	5.9e-06	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—breast cancer	1.15e-06	5.86e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAV1—breast cancer	1.07e-06	5.44e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—breast cancer	9.77e-07	4.96e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—breast cancer	8.59e-07	4.36e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—breast cancer	8.5e-07	4.31e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ALB—breast cancer	8.48e-07	4.3e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NOS3—breast cancer	8.11e-07	4.12e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—breast cancer	7.49e-07	3.8e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—breast cancer	7.42e-07	3.76e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—breast cancer	6.95e-07	3.52e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—breast cancer	6.47e-07	3.28e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—breast cancer	4.56e-07	2.32e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—breast cancer	3.73e-07	1.89e-06	CbGpPWpGaD
